Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $35.71

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $35.71.

DAWN has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, July 30th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. JPMorgan Chase & Co. cut their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Finally, Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the stock from $11.00 to $24.00 in a report on Thursday, August 1st.

Check Out Our Latest Report on DAWN

Insider Activity

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total transaction of $320,200.00. Following the transaction, the insider now directly owns 1,121,081 shares in the company, valued at $17,948,506.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total value of $320,200.00. Following the sale, the insider now owns 1,121,081 shares of the company’s stock, valued at $17,948,506.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 2,232 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the transaction, the insider now owns 1,127,535 shares of the company’s stock, valued at approximately $15,785,490. The disclosure for this sale can be found here. Insiders sold 68,748 shares of company stock worth $1,009,272 in the last 90 days. 8.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in Day One Biopharmaceuticals by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 452,934 shares of the company’s stock valued at $6,613,000 after buying an additional 5,796 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at $156,000. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at $29,000. Franklin Resources Inc. increased its position in Day One Biopharmaceuticals by 4.2% during the 4th quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock worth $61,857,000 after purchasing an additional 169,463 shares in the last quarter. Finally, NEOS Investment Management LLC purchased a new stake in Day One Biopharmaceuticals during the 4th quarter worth about $226,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $14.78 on Friday. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $18.07. The stock has a market cap of $1.29 billion, a P/E ratio of -5.89 and a beta of -1.51. The firm has a fifty day moving average price of $14.27 and a 200 day moving average price of $14.55.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last announced its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million. Sell-side analysts expect that Day One Biopharmaceuticals will post -1.68 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

(Get Free Report

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Further Reading

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.